Entolimod (CBLB502) is being developed by Cleveland Biolabs, Inc. for dual indications under the U.S. Food & Drug Administration's (FDA) animal efficacy rule as a pivotal-stage radiation countermeasure, and under the FDA's traditional drug approval pathway as a cancer treatment.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.